Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
Zanghì A, Borriello G, Bonavita S, Fantozzi R, Signoriello E, Barone S, Abbadessa G, Cellerino M, Ziccone V, Miele G, Lus G, Valentino P, Bucello S, Inglese M, Centonze D, Avolio C, D'Amico E.
Zanghì A, et al. Among authors: borriello g.
J Neurol. 2024 May 4. doi: 10.1007/s00415-024-12360-x. Online ahead of print.
J Neurol. 2024.
PMID: 38704488